Emile Nuwaysir, Ensoma CEO

Search­ing for the next 'big hairy goal,' Blue­Rock CEO Emile Nuwaysir jumps to in vi­vo cell ther­a­py start­up En­so­ma

Two years af­ter Bay­er swal­lowed the re­main­ing shares of his re­gen­er­a­tive cell ther­a­py com­pa­ny, Emile Nuwaysir has found him­self a new “big hairy goal”: in vi­vo cell ther­a­py.

En­so­ma, an am­bi­tious and well-backed start­up out of Fred Hutch and the Uni­ver­si­ty of Wash­ing­ton, has tapped Nuwaysir as the new CEO. It’ll be the se­r­i­al ex­ec­u­tive’s sec­ond stint as a CEO af­ter Blue­Rock, where he shep­herd­ed a first-of-its-kind cell ther­a­py for Parkin­son’s dis­ease in­to clin­i­cal tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.